Trials / Completed
CompletedNCT00473720
Phase I Study of the Combination of Satraplatin and Abraxane in Advanced Cancers
Phase I Dose Finding Study of the Orally Bioavailable Platinum Analog Satraplatin in Combination With Abraxane (Paclitaxel Protein-bound Particles) in Advanced Cancers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase I dose escalating study of oral satraplatin in combination with Abraxane administered weekly for three out of every four weeks in patients with advanced solid cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Satraplatin | Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5 |
| DRUG | Abraxane | Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2007-05-15
- Last updated
- 2013-01-23
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00473720. Inclusion in this directory is not an endorsement.